311 related articles for article (PubMed ID: 11054154)
21. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
[TBL] [Abstract][Full Text] [Related]
22. Do dopamine agonists provide neuroprotection?
Yamamoto M
Neurology; 1998 Aug; 51(2 Suppl 2):S10-2. PubMed ID: 9711974
[TBL] [Abstract][Full Text] [Related]
23. The benefits of pramipexole selection in the treatment of Parkinson's disease.
Silindir M; Ozer AY
Neurol Sci; 2014 Oct; 35(10):1505-11. PubMed ID: 25038745
[TBL] [Abstract][Full Text] [Related]
24. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
[TBL] [Abstract][Full Text] [Related]
25. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
26. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
27. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel MD
Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
[TBL] [Abstract][Full Text] [Related]
28. Pramipexole in patients with early Parkinson's disease.
Hubble JP; Koller WC; Cutler NR; Sramek JJ; Friedman J; Goetz C; Ranhosky A; Korts D; Elvin A
Clin Neuropharmacol; 1995 Aug; 18(4):338-47. PubMed ID: 8665547
[TBL] [Abstract][Full Text] [Related]
29. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic evaluation of pramipexole.
Antonini A; Calandrella D
Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1307-14. PubMed ID: 21892895
[TBL] [Abstract][Full Text] [Related]
31. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
Bonuccelli U; Colzi A; Del Dotto P
Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
[TBL] [Abstract][Full Text] [Related]
33. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
[TBL] [Abstract][Full Text] [Related]
34. [Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Grandas F; Galiano ML
Neurologia; 1999 May; 14(5):224-8. PubMed ID: 10377723
[TBL] [Abstract][Full Text] [Related]
35. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
[TBL] [Abstract][Full Text] [Related]
36. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
[TBL] [Abstract][Full Text] [Related]
37. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
38. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
39. [Pramipexole in Parkinson disease. Results of a treatment observation].
Reichmann H; Brecht HM; Kraus PH; Lemke MR
Nervenarzt; 2002 Aug; 73(8):745-50. PubMed ID: 12242961
[TBL] [Abstract][Full Text] [Related]
40. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
